Clinical Trial Update: Imatinib Mesylate After Irinotecan and Cisplatin in Treating Patients With Extensive-Stage Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluated imatinib mesylate after irinotecan and cisplatin in patients with extensive-stage small cell lung cancer; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Extensive-stage Small Cell Lung Cancer

Drugs mentioned

• Imatinib mesylate (Imatinib)

Snippet

Sponsor: Barbara Ann Karmanos Cancer Institute | Conditions: Lung Cancer | Phase 2 | Status: COMPLETED